NanoMab   Report issue

For profit Phase 1
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2019
NCT04040686
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

NanoMab

Active Ingredients

Drugs in Phase 1 Trials (4)

188re-nm-02 (1 trial)

68ga-psma (1 trial)

99m-tc-nm-02 (2 trials)

thp-psma (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 4